Literature DB >> 9114771

Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.

S Take1, M Matsutani, H Ueda, H Hamaguchi, H Konishi, Y Baba, H Kawaratani, T Sugiura, T Iwasaka, M Inada.   

Abstract

This study sought to evaluate the effect of cilostazol in preventing restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) in 68 patients: 35 patients received cilostazol immediately after PTCA and 33 patients received aspirin or ticlopidine. Repeat coronary angiography was performed 4 to 6 months after PTCA and the incidence of restenosis was significantly lower (17%) in the cilostazol group than in the non-cilostazol group (40%) (p < 0.05), which indicates that cilostazol has the potential to prevent restenosis after PTCA.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9114771     DOI： 10.1016/s0002-9149(97)00052-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  G-protein-mediated signaling in vascular smooth muscle cells - implications for vascular disease.

Authors:  Till F Althoff; Stefan Offermanns
Journal:  J Mol Med (Berl)       Date:  2015-06-14       Impact factor: 4.599

2.  The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.

Authors:  Ying Xue; Zhi-Wei Feng; Xiao-Ye Li; Zi-Heng Hu; Qing Xu; Zi Wang; Jia-Hui Cheng; Hong-Tao Shi; Qi-Bing Wang; Hong-Yi Wu; Xiang-Qun Xie; Qian-Zhou Lv
Journal:  Acta Pharmacol Sin       Date:  2017-09-21       Impact factor: 6.150

Review 3.  Drug treatment of intermittent claudication.

Authors:  Douglas Jacoby; Emile R Mohler
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  The vascular effects of cilostazol.

Authors:  William S Weintraub
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 5.  Nanoparticulate carriers for the treatment of coronary restenosis.

Authors:  Luis Brito; Mansoor Amiji
Journal:  Int J Nanomedicine       Date:  2007

6.  Microbe-Derived Butyrate and Its Receptor, Free Fatty Acid Receptor 3, But Not Free Fatty Acid Receptor 2, Mitigate Neointimal Hyperplasia Susceptibility After Arterial Injury.

Authors:  Michael Nooromid; Edmund B Chen; Liqun Xiong; Katherine Shapiro; Qun Jiang; Falen Demsas; Maeve Eskandari; Medha Priyadarshini; Eugene B Chang; Brian T Layden; Karen J Ho
Journal:  J Am Heart Assoc       Date:  2020-06-25       Impact factor: 5.501

7.  A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine.

Authors:  Ichiro Ikushima; Kazuchika Yonenaga; Hironao Iwakiri; Hideki Nagoshi; Haruhito Kumagai; Yasuyuki Yamashita
Journal:  Med Devices (Auckl)       Date:  2011-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.